Rate My Professor Vern Bowles

Bowles' key research contributions include identifying metalloprotease enzymes in head louse egg shells and developing abametapir as an inhibitor, leading to Xeglyze, a single-application topical lotion approved by the US Food and Drug Administration in 2020 for treating head lice infestations by killing both adults and unhatched eggs. His work extends to blowfly strike by Lucilia cuprina, investigating excretory-secretory products for wound initiation, innate immune responses in breech strike-resistant sheep, and flystrike vaccine development. Additional efforts address scabies treatments combining abametapir and flavesone. Notable publications comprise 'In vitro assessment of a combination therapy of abametapir and flavesone as a novel topical single-dose scabies treatment' (2026), 'A Randomized, Double-blind, Vehicle-controlled Study of the Ovicidal Efficacy of a New Head Lice Therapy, Abametapir Lotion, 0.74%' (2021), 'Effect of a New Head Lice Treatment, Abametapir Lotion, 0.74%, on Louse Eggs: A Randomized, Double-Blind Study' (2016), 'Characterization of ES products involved in wound initiation by Lucilia cuprina larvae' (1995), and 'Characterising the innate immune response in breech strike resistant and non-selected sheep to the sheep blowfly (Lucilia cuprina)' (2023). He has featured in expert podcasts on ectoparasites.